A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis

202375 citationsJournal Articlehybrid Open Access

Authors

Aldafermin 3 mg resulted in a significant reduction in Enhanced Liver Fibrosis in patients with compensated NASH cirrhosis.

Good health and well-being

Published in: Hepatology

Volume 79, Issue 3, pp. 674-689

Field-Weighted Citation Impact: 16.10